Mebendazole as Adjuvant Treatment for Colon Cancer

Phase 3

Recruiting

• Conditions: Colorectal Cancer
• Interventions: Drug: Folfox with avastin; Drug: Mebendazole

• Registration Number: NCT03925662
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

mebendazole treating colon cancer

Detailed Description

mebendazole as adjuvant treatment for colon cancer

Study Timeline

• Status Verified: 2019-04
• Study Start: 2019-04-01
• Study First Submitted: 2019-04-22
• Study First Submitted QC: 2019-04-22
• Last Update Submitted: 2019-04-22
• Study First Posted: 2019-04-24
• Last Update Posted: 2019-04-24
• Primary Completion: 2028-12
• Study Completion: 2028-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Colorectal cancer stage 4.

Exclusion Criteria

• Agranulocytosis
• Pregnancy
• Allergy to mebendazole.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Folfox with avastin	Folfox with avastin	Folfox with avastin only
Mebendazole	Mebendazole	Folfox with avastin with mebendazole

Primary Outcome Measures

Name	Time	Method
number of patients with tumour response	6 months	number of patients with response

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Cairo, Egypt